Patents Examined by Jennifer E. Graser
  • Patent number: 10908151
    Abstract: The present disclosure provides compositions comprising a food product, non-pathogenic microorganism, kits, methods of diagnosing a tumor in a subject, methods of quantifying the number of cancer cells in a cell sample, and methods of detecting a cancer cell, cancer tissue, or cell associated with a hyperproliferative disorder. In some embodiments, the method comprises a step of detecting the presence or absence of a modified substrate or portion thereof in urine of an animal without an instrument and solely by visual inspection of the urine.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 2, 2021
    Assignees: Massachusetts Institute of Technology, The Regents of the University of California
    Inventors: Tal Danino, Sangeeta N. Bhatia, Arthur Prindle, Jeff Hasty
  • Patent number: 10908160
    Abstract: The object is to provide a lysis method and lysis treatment solution for efficiently lysing cells of various Streptococcus bacteria in milk of a livestock animal to release a specific antigen substance contained in the cells for detecting whether causative bacterium of mastitis is a Streptococcus bacterium or not by using the milk, as well as a detection method using an immunochromatographic device. There is provided a method for lysing a Streptococcus bacterium, which comprises the step of mixing a lysis agent containing a lytic enzyme with milk obtained form a livestock animal to lyse a Streptococcus bacterium existing in the milk. The lytic enzyme is preferably at least one selected from the group consisting of lysozyme, labiase, and ?-N-acetylglucosaminidase.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: February 2, 2021
    Assignee: ASAHI KASEI KABUSHIKI KAISHA
    Inventors: Takamitsu Utsumi, Koji Maehana, Kenji Matsuyama
  • Patent number: 10906989
    Abstract: We provide new monoclonal antibody inhibitors of coagulases for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus and inhibiting SC-ProT activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the staphylocoagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: February 2, 2021
    Inventor: William R Church
  • Patent number: 10897922
    Abstract: A composition and method for activating probiotic spores in food and beverage products, such as steeped teas, coffee, soups, and sauces. A nutrient-germinant composition comprises one or more L-amino acids, optionally one or more buffers to maintain the pH of the composition when added to water in a range of around 6-8, optionally D-glucose, D-fructose, or both D-glucose and D-fructose, and optionally, an osmoprotectant. The nutrient-germinant composition, one or more species of Bacillus spores, and a food or beverage product may be pre-mixed in any combination. Water is added to the mixture and heated to a temperature range of 42 to 100° C. to germinate the probiotic spores prior to being consumed.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: January 26, 2021
    Assignee: NCH Corporation
    Inventors: Jordan E. Church, Gabriel F. K. Everett, Charles J. Greenwald, Lester Levy, Judy Pruitt, Amanda Rosmarin, Daniel Aberle, George Aboagye
  • Patent number: 10869914
    Abstract: A method for treating an abnormality of the first metatarsophalangeal joint of the foot of a mammal includes electrically stimulating a site on each of the extensor hallucis brevis and adductor hallucis muscles of a foot of the mammal affected by the abnormality, and visually confirming that the stimulated muscles responds to the stimulation by contracting. An amount of botulinum toxin effective to treat the abnormality is then injected to the confirmed sites on the extensor hallucis brevis and the adductor hallucis muscles of the affected foot.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: December 22, 2020
    Inventor: Philip Andrew Radovic
  • Patent number: 10865435
    Abstract: Embodiments of the present disclosure relate to methods of screening and optionally designing compounds as inhibitors of Mfd (Mutation Frequency Decline), such compounds being useful for the treatment of bacterial infections. Embodiments of the methods include culturing pathogenic bacteria expressing functional Mfd with various concentrations of 1 mM or less, incubating the cultures with and without nitric oxide stress conditions, evaluating bacterial survival in each of the cultures, and calculating the concentration of the molecule required to decrease by 50% the survival rate of the bacteria (IC50) by comparing the cfu of the untreated cultures and cultures following nitric oxide stress.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: December 15, 2020
    Assignees: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURG
    Inventors: Nalini Rama Rao, Didier Rognan, Didier Lereclus
  • Patent number: 10864235
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: December 15, 2020
    Assignee: Seres Therapeutics, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David Arthur Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Patent number: 10864266
    Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: December 15, 2020
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Thomas J. Silhavy, Marcin Grabowicz, Daniel Kahne, Matthew Lebar, Dorothee Andres
  • Patent number: 10864260
    Abstract: The present invention relates to new protein compositions, methods for producing said protein compositions, pharmaceutical compositions comprising said protein compositions and methods for treating infections caused by Neospora caninum. In particular, the present invention relates to a protein composition comprising the proteins specified in Table A in an amount of at least about 2 times (fold change) higher than the same protein present in the whole tachyzoite, as calculated by quantitative label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS).
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 15, 2020
    Assignee: UNIVERSIDAD COMPLUTENSE DE MADRID
    Inventors: Javier Regidor Cerrillo, David Arranz Solís, Esther Collantes Fernández, Gema Álvarez García, Luis Miguel Ortega Mora
  • Patent number: 10851137
    Abstract: The present invention relates to Roseburia flagellin, and/or a polynucleotide sequence encoding said Roseburia flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: December 1, 2020
    Assignee: 4D Pharma Research Limited
    Inventors: Denise Kelly, Angela Patterson, Edouard Monnais, Imke Mulder
  • Patent number: 10852286
    Abstract: The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: December 1, 2020
    Assignee: Intervet, Inc.
    Inventors: Michelle Allen, Mark Garrett, Urs Peter Bruderer, Martinus Antonius Johannes Thijssen
  • Patent number: 10842843
    Abstract: Methods and products for producing an antigen specific immune response are provided. The methods involve administration of a caspase inhibitor to a subject.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: November 24, 2020
    Assignee: The University of Vermont and State Agricultural College
    Inventors: Ralph C. Budd, Cheryl Collins
  • Patent number: 10835563
    Abstract: The present invention provides a method for preventing, postponing or treating ocular diseases, including changes in the anterior/posterior chamber volume, vitreous humour, and/or retinal detachment. The method comprises administering to a subject an effective amount of Cordyceps cicadae mycelium active substances. A method for preparing Cordyceps cicadae mycelium active substances comprises following steps: (a) culturing a Cordyceps cicadae mycelium on a plate medium between 15-35° C. for 5-14 days; (b) inoculating the Cordyceps cicadae mycelium of step (a) into a flask and culturing the mycelium between 15-35° C. and pH 2-8 for 3-7 days; and (c) inoculating the Cordyceps cicadae mycelium of step (b) into a fermenter tank and culturing the mycelium by stirring between 15-35° C. and pH 2-8 for 3-5 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid containing the Cordyceps cicadae mycelium active substances.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 17, 2020
    Assignee: GRAPE KING BIO LTD.
    Inventors: Chin-Chu Chen, Shu-Hsing Yeh, Li-Ya Lee, Jui-Hsia Hsu
  • Patent number: 10836839
    Abstract: The invention relates to a method for the removal of protein and other impurities from microbial capsular polysaccharides. More particularly, the present invention relates to isolation of microbial capsular polysaccharides in pure form after removal of protein and other impurities.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: November 17, 2020
    Assignee: BIOLOGICAL E LIMITED
    Inventors: Ramesh Venkat Matur, Vivek Babu Kandimalla, Narender Dev Mantena, Mahima Datla, Muthyala Venkateswara Reddy, Kantam Charan
  • Patent number: 10837041
    Abstract: The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: November 17, 2020
    Assignee: EVOLVA SA
    Inventors: Veronique Douchin, Michael Dalgaard Mikkelsen, Iben Møller-Hansen
  • Patent number: 10821167
    Abstract: The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from Staphylococcus aureus (SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: November 3, 2020
    Assignee: UNM Rainforest Innovations
    Inventors: Pamela Hall, Bryce Chackerian, David S. Peabody, Seth Michael Daly, Bradley Owen Elmore, Kathleen Triplett
  • Patent number: 10792351
    Abstract: Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: October 6, 2020
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: John R. Barta, Luc Berghman, Srichaitanya Shivaramaiah, Olivia B. Faulkner, Lisa Bielke, Billy Hargis
  • Patent number: 10793623
    Abstract: The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: October 6, 2020
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Samuel Lai, M. Gregory Forest, Christine Henry, Timothy Wessler, Alexander Chen, Jennifer Schiller, Jay Newby
  • Patent number: 10787504
    Abstract: The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular multidrug resistant (MDR) MTB and extremely drug resistant (XDR) MTB. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to MTB and/or antibodies that are specifically reactive to MTB antigens. The greater activity of the immune system generated by a vaccine of the invention increases generation of memory T cells that provide for a greater and/or extended response to an MTB infection. Responses involve an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: September 29, 2020
    Assignee: Longhorn Vaccines and Diagnostics, LLC
    Inventors: Gerald W. Fischer, Luke T. Daum, Richard F. Schuman, Clara J. Sei
  • Patent number: 10788493
    Abstract: The present invention relates to a composition for diagnosing infectious diseases by using a tryptophanyl-tRNA synthase (WRS) and a method for detecting a diagnostic marker and, more specifically, to: a composition for diagnosing infectious diseases, containing a preparation measuring the WRS protein or mRNA expression level; a diagnostic kit; a method for detecting the WRS for providing information required for the diagnosis of infectious diseases, and a method for determining the infectious disease mortality risk by using the WRS. According to the present invention, the WRS is increased only in infection-induced infectious diseases, differentiating non-infectious diseases therefrom, and is rapidly increased in the early stage of infection. In addition, the level of the WRS is closely correlated with the severity and prognosis of diseases or complications induced by infection.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: September 29, 2020
    Assignee: JW BIOSCIENCE
    Inventors: Sunghoon Kim, Mi Rim Jin, Young Ha Ahn